

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/171078 A1

(51) International Patent Classification:
C07K 16/26 (2006.01) A61K 39/395 (2006.01)
A61P 43/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2024/051380

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:
14 February 2024 (14.02.2024)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/484,850 14 February 2023 (14.02.2023) US

(71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9,
2500 VALBY (DK).

(72) Inventors: ASUNI, Ayodeji Abdur-Rasheed; Ottiliavej 9,
2500 Valby (DK). ROHE, Michael; Ottiliavej 9, 2500 Val-
by (DK). PRADHAN, Amynah; c/o University of Illinois,
Dept. Psychiatry, 1601 W. Taylor Street, Chicago, Illinois
60612 (US). SIEGERSMA, Kendra; c/o University of Illi-
nois, Dept. Psychiatry, 1601 W. Taylor Street, Chicago, Illi-
nois 60612 (US). MANGUTOV, Elizaveta; c/o University
of Illinois, Dept. Psychiatry, 1601 W. Taylor Street, Chica-
go, Illinois 60612 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATMENT OF OPIOD-INDUCED PAIN

(57) Abstract: The present invention is directed to a method for treatment of pain, such as hyperalgesia or allodynia, more specifically treatment of opioid-induced pain, such as opioid-induced chronic migraine, opioid-induced hyperalgesia (OIH), and opioid-induced allodynia (OIA), by administration of an antibody and/or antigen-binding fragment thereof having binding specificity for PACAP. The antibody and/or antigen-binding fragment thereof may comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The antibody and/or antigen-binding fragment thereof described herein binds to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody.



WO 2024/171078 A1